P895: DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE (D-VD) VERSUS BORTEZOMIB AND DEXAMETHASONE (VD) ALONE IN CHINESE PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED ANALYSIS OF LEPUS

Documenti analoghi

• P895: DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE (D-VD) VERSUS BORTEZOMIB AND DEXAMETHASONE (VD) ALONE IN CHINESE PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED ANALYSIS OF LEPUS
  di: W. Fu, et al.
  Pubblicazione: (2022-06-01)
• Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR
  di: Andrew Spencer, et al.
  Pubblicazione: (2018-12-01)
• A phase 2 study of Daratumumab with Thalidomide and dexamethasone in relapsed and/or Refractory Myeloma (RRMM)
  di: Chandramouli Nagarajan, et al.
  Pubblicazione: (2025-06-01)
• Upfront Daratumumab With Lenalidomide and Dexamethasone for POEMS Syndrome
  di: Maria Gavriatopoulou, et al.
  Pubblicazione: (2020-06-01)
• Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group
  di: Francesca Fazio, et al.
  Pubblicazione: (2022-02-01)